GKOS
Glaukos Corporation

910
Mkt Cap
$4.32B
Volume
883,868.00
52W High
$163.71
52W Low
$73.73
PE Ratio
-45.42
GKOS Fundamentals
Price
$75.26
Prev Close
$76.63
Open
$76.21
50D MA
$86.59
Beta
1.22
Avg. Volume
845,420.71
EPS (Annual)
-$2.77
P/B
5.63
Rev/Employee
$385,408.04
Loading...
Loading...
News
all
press releases
DexCom (DXCM) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
DexCom (DXCM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·13h ago
News Placeholder
More News
News Placeholder
Will Glaukos (GKOS) Report Negative Earnings Next Week? What You Should Know
Glaukos (GKOS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·2d ago
News Placeholder
Glaukos Innovation to be Highlighted at the 2025 American Academy of Ophthalmology Annual Meeting
Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases...
Business Wire·10d ago
News Placeholder
Glaukos Builds Dual Growth Engines Amid Market Headwinds
GKOS raises revenue guidance after record 1H sales, fueled by iDose TR adoption and expanding international glaucoma momentum.
Zacks·2mo ago
News Placeholder
GKOS Stock Falls Despite Q2 Earnings & Revenues Beat, Guidance Raised
Glaukos' second-quarter results showcase a strong uptick in revenues. However, continued operating loss remains a cause of concern.
Zacks·3mo ago
News Placeholder
Glaukos (GKOS) Reports Q2 Loss, Tops Revenue Estimates
Glaukos (GKOS) delivered earnings and revenue surprises of +7.69% and +8.06%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Glaukos Ramps Up iDose TR, Battles Legacy and Reimbursement Risks
GKOS posts record Q1 on iDose TR strength, but reimbursement hurdles and legacy declines may hurt its near-term outlook.
Zacks·4mo ago
News Placeholder
What Makes Glaukos (GKOS) a New Buy Stock
Zacks·4mo ago
News Placeholder
Can Glaukos (GKOS) Climb 34.4% to Reach the Level Wall Street Analysts Expect?
Zacks·4mo ago
News Placeholder
Here's Why You Should Retain Glaukos Stock in Your Portfolio
Zacks·5mo ago

Latest GKOS News

View

Advertisement|Remove ads.

Advertisement|Remove ads.